Novellia, a patient-powered real-world data platform, announced that it has raised $18 million in Series A funding led by Spark Capital, with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV. The new financing brings the company’s total funding to $28 million and comes as Novellia expands its presence among major pharmaceutical companies and launches a new patient-facing mobile application.
The company says it is addressing a significant challenge in healthcare research, where pharmaceutical companies and researchers often rely on fragmented datasets assembled from insurance claims and hospital records. According to Novellia, the current real-world data ecosystem costs more than $50 billion annually while frequently lacking complete patient information.
Founded to place patients at the center of medical research, Novellia enables individuals to securely access, organize, and manage their health histories while giving them the option to contribute anonymized and deidentified data to scientific research efforts. The company’s platform is already being used by several of the world’s largest pharmaceutical companies and diagnostics organizations, and it recently signed multiple seven-figure, multi-year contracts.
Novellia plans to use the new capital to expand its AI-powered technology platform. The company’s system helps patients aggregate medical records from hospitals, physician offices, and laboratories across the United States into a single unified health record. Novellia then applies proprietary natural language processing models to analyze unstructured clinical information such as physician notes, laboratory narratives, and diagnostic reports, creating research-ready datasets for life sciences organizations.
The company says its platform can help patients consolidate up to 20 years of medical data in approximately 30 seconds, reducing administrative burdens for individuals managing complex or chronic health conditions.
Alongside the funding announcement, Novellia unveiled a new mobile application that extends the functionality of its existing online platform, enabling patients to securely access their complete health histories through a mobile experience.
Novellia has received recognition from several healthcare and digital health organizations, including being named one of Digital Health New York’s startups to watch and receiving awards for innovation in drug development and healthcare data management. The company also notes that its platform is supported by peer-reviewed research presented at major medical conferences, including ASCO and SABCS-AACR.
KEY QUOTES:
“Behind every patient is a fragmented, incomplete record of their life. I watched this up close: first through my grandfather’s cancer journey, and then professionally in pharma, where we were developing therapies without ever seeing the full picture. The system failed patients and researchers at the same time. Novellia changes the course for this whole industry by putting the patient at the center.”
Shashi Shankar, Co-Founder and CEO, Novellia
“I’ve known major pharma companies had data that was too old, too slow, and too disconnected from patients. For a long time, I looked for a company like Novellia. Shashi understood the problem firsthand and built the solution that benefits patients and research. Since Spark led the Series A, Novellia has signed some of the largest companies in the world to seven-figure, multi-year contracts. This is dramatically changing how medicines are developed.”
Alex Finkelstein, General Partner, Spark Capital
“Nearly 70% of patients are open to contributing data for medical breakthroughs, but they expect control, transparency, and privacy safeguards. That gap between willingness and infrastructure is exactly what Novellia solves by creating a new category of patient-consented data that is both more complete and more actionable for research.”
Emma Silverman, Partner, TMV
